MPLT News
Archived Headlines
- US IPO Week Ahead: First major post-shutdown launches set to IPO 10/24/25
- CNS disorder biotech MapLight Therapeutics sets terms for $251 million IPO 10/06/25
- US IPO Weekly Recap: Large listings continue to draw interest in 6 IPO week, as pipeline grows 09/19/25
- CNS disorder biotech MapLight Therapeutics files for a $100 million IPO 09/19/25
Biotech IPOs are back: Why 2026 could mark a hot year for the sector
After a period of uneven performance, the biotech IPO market is beginning to show signs of renewed momentum. On Monday, radiopharmaceutical oncology biotech Aktis Oncology (AKTS) launched a $200 million IPO; two days later, the company upsized the deal by 50%...read more
Renaissance Capital's October IPO Market Update
The long-awaited IPO pickup lost some of its steam in October, as the US government shutdown disrupted timelines and delayed deal activity. Twenty-two IPOs raised a combined $3.2 billion, in line with the 10-year historical average by deal count (21) but well...read more
US IPO Weekly Recap: Navan slips, and Medline joins the pipeline to close out October
Three sizable IPOs and four SPACs debuted this week to wrap up October. Three IPOs submitted initial filings. Corporate travel software provider Navan (NAVN) priced its IPO at the midpoint to raise $923 million at a $6.9 billion market cap. The company...read more
CNS disorder biotech MapLight Therapeutics prices IPO at $17, as expected
MapLight Therapeutics, a Phase 2 biotech developing therapies for neuropsychiatric and CNS disorders, raised $251 million by offering 14.8 million shares at $17. Cornerstone investor T. Rowe Price had indicated on $40 million worth of shares in the offering (16%...read more